Business Wire

EPSILON-ADVANCED

2.2.2024 17:28:29 CET | Business Wire | Press release

Share
EAM Completes Acquisition of LFP Cathode Technology Center in Germany, Plans for Commercial Scale Production for Global Supply Chain

Epsilon Advanced Materials (EAM) today finalized the acquisition of a lithium-ion phosphate (LFP) cathode active material technology center in Moosburg, Germany, making it the first global company capable of providing manufacturers with both cathode and anode materials for lithium-ion batteries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240201488246/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Vikram Handa, Managing Director, Epsilon Advanced Materials (center), stands with employees at the lithium-ion phosphate (LFP) cathode active material technology center in Moosburg, Germany. Epsilon Advanced Materials acquired the facility, positioning the company to lead the electric vehicle battery industry in cathode material manufacturing. (Photo: Business Wire)

With the purchase, EAM is poised to make India the first country in Asia outside of China to manufacture LFP cathode materials. Approximately 70% of cathode materials, and 100% of LFP cathode, for lithium-ion batteries are currently produced in China.

“This acquisition reaffirms our commitment to delivering cutting-edge solutions to the evolving EV battery market,” said Vikram Handa, managing director of EAM. "The advanced technology center in Moosburg strategically positions us to lead the industry in cathode material manufacturing.”

Acquiring the cathode active material technology center from Johnson Matthey solidifies EAM’s position as a global EV battery materials provider, with the potential to reshape the landscape of electric mobility by reducing the battery market’s reliance on China.

Epsilon previously announced a $1.1 billion investment for the establishment of an anode battery materials manufacturing facility in Bellari, Karnataka, India. EAM also plans to build a $650 million graphite anode material manufacturing facility in Brunswick County, North Carolina, U.S. and is investing Euro 600 million to develop a graphite processing facility in Vaasa, Finland.

"We are proud to announce that EAM is now ready to go to market with a proven high-performance cathode active material, marking a significant leap forward in our capabilities,” said EAM CEO Sunit Kapur “Integrating the cathode expertise from the Moosburg technology center with our anode business uniquely positions us to deliver comprehensive solutions to customers, delivering anode and cathode to empower them to optimize the performance of their batteries.”

Battery manufacturers are increasingly transitioning to LFP cathode, which has a longer life span, offers improved discharge and charge efficiency, provides better performance in higher temperatures and is less expensive compared to other cathode materials, such as nickel and cobalt, and it also is maintenance-free, extremely safe and lightweight.

EAM is scheduled to break ground on its facility in India in 2024 to build a large-scale customer qualification plant in 2025, which will scale up to 100,000 tons by 2030.

The Moosburg facility, which employs approximately 25 people in its R&D and operations greatly reduces EAM’s technology development and scale-up timeframe. The center is equipped to produce LFP and lithium manganese iron phosphate (LMFP) cathode in small laboratory-scale batches to up pilot-scale material. It features a versatile pilot customer qualification plant designed to validate new materials and utilizes a Hydrothermal process that provides a cleaner metal processing solution, which results in a more environmentally friendly battery-metals supply chain.

About Epsilon Advanced Materials

Epsilon Advanced Materials is at the forefront of battery material solutions, producing high-caliber, innovative, and environmentally conscious lithium-ion battery (LiB) materials. Founded in 2018 and headquartered in Mumbai, Epsilon's mission resonates with supporting the global battery industry's transition to clean and green energy. With a significant presence spanning Europe, North America, and South-East Asia, Epsilon continues to set industry benchmarks. https://www.epsilonam.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201488246/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye